疏风解毒胶囊预防给药对流感病毒感染小鼠模型TLR4介导肺组织炎性损伤的影响

doi:10.19803/j.1672-8629.20230419

中国药物警戒 ›› 2024, Vol. 21 ›› Issue (1): 45-50.
DOI: 10.19803/j.1672-8629.20230419

• 呼吸道病毒性疾病与中医药防治机制研究专栏 • 上一篇下一篇

疏风解毒胶囊预防给药对流感病毒感染小鼠模型TLR4介导肺组织炎性损伤的影响

曹姗, 庞博, 徐英莉, 张敬升, 陈梦苹, 张宇, 王雅欣, 包蕾, 耿子涵, 郭姗姗, 赵荣华^#, 崔晓兰^*

中国中医科学院中药研究所生物安全实验室,北京 100700

收稿日期:2023-07-03 出版日期:2024-01-15 发布日期:2024-01-18
通讯作者: ^*崔晓兰,女,博士,研究员,中药抗病毒与抗感染药理。E-mail:cuixiaolan2812@126.com; ^#为共同通信作者。
作者简介:曹姗,女,在读博士,中药药理。
基金资助:
国家自然科学基金资助项目（82141206）; 中国中医科学院科技创新工程（CI2021A04606）

Effects of Shufeng Jiedu capsules prophylactic administration on TLR4-mediated inflammatory injury in lung tissue in a mouse model of inffuenza virus infeciton

CAO Shan, PANG Bo, XU Yingli, ZHANG Jingsheng, CHEN Mengping, ZHANG Yu, WANG Yaxin, BAO Lei, GENG Zihan, GUO Shanshan, ZHAO Ronghua^#, CUI Xiaolan^*

Biosecurity Laboratory, Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China

Received:2023-07-03 Online:2024-01-15 Published:2024-01-18

摘要/Abstract

摘要： 目的探究疏风解毒胶囊预防给药对甲型流感病毒肺炎小鼠的影响及可能的干预机制。方法采用甲型H1N1流感病毒（FM1株）滴鼻感染ICR小鼠,构建病毒性肺炎模型。每日固定时间观察各组小鼠一般状态,计算各组小鼠肺指数、抑制率和病毒载量;采用Micro-CT、苏木精-伊红染色（HE）法观察小鼠肺组织病理形态变化;采用酶联免疫吸附法（ELISA）检测肺组织中肿瘤坏死因子（TNF-α）、白介素-6（IL-6）的含量;蛋白免疫印迹法（Western blot）检测肺组织中TLR4、MyD88蛋白的表达含量。结果预防性给予疏风解毒胶囊可降低小鼠的肺指数,降低肺组织中病毒载量,修复流感小鼠肺部损伤,减轻肺部病变,降低肺组织中TNF-α和IL-6含量。Western blot结果显示疏风解毒胶囊可下调肺组织TLR4、MyD88蛋白的表达。结论疏风解毒胶囊预防性给药对甲型流感病毒肺炎小鼠具有保护作用,其机制与抑制病毒复制、改善肺组织病变、抑制炎症因子释放和下调肺组织中TLR4、MyD88蛋白的表达有关。关键词：甲型流感病毒;疏风解毒胶囊;抗病毒作用;TLR4/MyD88;小鼠;肺组织;肺炎

关键词: 甲型流感病毒, 疏风解毒胶囊, 抗病毒作用, TLR4/MyD88, 小鼠, 肺组织, 肺炎

Abstract: Objective To investigate the effects of prophylactic administration of Shufeng Jiedu capsules on mice withinfluenza A virus pneumonia and the possible mechanisms of intervention. Methods Influenza A (H1N1) virus (FM1 strain) was used to infect ICR mice with nasal drops to construct a viral pneumonia model. The general status of mice in each group was observed at a fixed time every day, and the lung index, inhibition rate, and viral load of mice in each group were calculated; Micro-CT and hematoxylin-eosin staining (HE) were used to observe histomorphological changes in mouse lungs; An enzyme-linked immunosorbent assay (ELISA) was used to detect the levels of tumor necrosis factor (TNF-α) and interleukin-6 (IL-6) in lung tissues; protein immunoblotting (Western blot) was used to detect the expression levels of TLR4 and MyD88 proteins in lung tissues. Results Prophylactic administration of Shufeng Jiedu capsules reduced lung index, decreased viral load in lung tissue, repaired lung damage, attenuated lung lesions and decreased TNF-α and IL-6 levels in lung tissues in mice with influenza. Western blot results showed that Shufeng Jiedu capsules could down-regulatethe expression of TLR4 and MyD88 proteins in lung tissue. Conclusion Prophylactic administration of Shufeng Jieducapsules had a protective effect in mice with influenza A virus pneumonia. The mechanism is related to the inhibition of viral replication, improvement of lung tissue lesions, inhibition of inflammatory factor release and down-regulation of TLR4 and MyD88 protein expression in lung tissue.

Key words: influenza A virus, Shufeng Jiedu capsules, anti-viral effect, TLR4/MyD88, mice, lung tissue, pneumonia

中图分类号:

R978
R994.1

曹姗, 庞博, 徐英莉, 张敬升, 陈梦苹, 张宇, 王雅欣, 包蕾, 耿子涵, 郭姗姗, 赵荣华, 崔晓兰. 疏风解毒胶囊预防给药对流感病毒感染小鼠模型TLR4介导肺组织炎性损伤的影响[J]. 中国药物警戒, 2024, 21(1): 45-50.

CAO Shan, PANG Bo, XU Yingli, ZHANG Jingsheng, CHEN Mengping, ZHANG Yu, WANG Yaxin, BAO Lei, GENG Zihan, GUO Shanshan, ZHAO Ronghua, CUI Xiaolan. Effects of Shufeng Jiedu capsules prophylactic administration on TLR4-mediated inflammatory injury in lung tissue in a mouse model of inffuenza virus infeciton[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 45-50.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://www.zgywjj.com/CN/10.19803/j.1672-8629.20230419

https://www.zgywjj.com/CN/Y2024/V21/I1/45

参考文献

[1] DU DD, LIU B, SHI W, et al.Analysis of influenza pathogen surveillance in Ankang from 2016 to 2018[J]. J Med Pest Control(医学动物防制), 2020, 36(11): 1038-1041.
[2] FU YJ.Effects of different traditional Chinese medicines on TLR7/NF-κB signaling pathway in mice infected with influenza virus FM1 in normal environment and damp-heat environment[D]. Guangzhou: Jinan University, 2021.
[3] JIN Y.Research on the evolution of major subtypes in influenza A virus[D]. Beijing: Academy of Military Sciences, 2015.
[4] WEI X, NARASIMHAN H, ZHU B, et al.Host recovery from respiratory viral infection[J]. Annu Rev Immunol, 2023, 41: 277-300.
[5] ZHU Q, PAN J, XU J, et al.Research progress on Shufeng Jiedu Capsules in treatment of respiratory infectious diseases[J]. Chinese Traditional and Herbal Drugs(中草药), 2022, 53(11): 3557-3563.
[6] BAO YY, GAO YJ, SHI YJ, et al.Study on broad-spectrum antiviral effect of Shufeng Jiedu Capsules[J]. New Chinese Medicine(新中医), 2019, 51(12): 5-8.
[7] XU YL, XUE YL, ZHANG HH, et al.Clinical observation on treatment of acute upper respiratory infection of wind-heat syndrome with Shufeng Jiedu Capsules[J]. Journal of Traditional Chinese Medicine(中医杂志), 2015, 56(8): 676-679.
[8] XI ZQ, ZHOU JZ, MEI JQ, et al.Clinical study about the effect on the fever caused by viral upper respiratory tract infection[J]. Chinese Medicine Modern Distance Education of China(中国中医药现代远程教育), 2010, 8(17): 162-164.
[9] CHEN YB, LIN L, WU MH, et al.Research ideas and methods of “diaphoresis,harmonizing,clearing and purgative, expelling pathogens from both interior and exterior ”in treatment of influenza[J]. Liaoning Journal of Traditional Chinese Medicine(辽宁中医杂志), 2018, 45(1): 50-52.
[10] YANG C.Progress and prospects of the application of Chinese medicine in influenza control[J]. Journal of Traditional Chinese Medicine Management(中医药管理杂志), 2023, 31(6): 226-228.
[11] XIE P, WANG CQ, YE YH, et al.Virtual screening of the active ingredients of Shufeng Jiedu Capsule for COVID-19 based on molecular docking and network pharmacology[J]. Journal of Pharmaceutical Research(药学研究), 2021, 40(9): 590-597, 604.
[12] YUAN Y, LIAO Q, XUE M, et al.Shufeng Jiedu Capsules alleviate lipopolysaccharide-induced acute lung inflammatory injury via activation of GPR18 by verbenalin[J]. Cell Physiol Biochem, 2018, 50(2): 629-639.
[13] XIA L, SHI Y, SU J, et al.Shufeng Jiedu, a promising herbal therapy for moderate COVID-19:Antiviral and anti-inflammatory properties, pathways of bioactive compounds, and a clinical real-world pragmatic study[J]. Phytomedicine, 2021, 85: 153390.
[14] BAI J, ZHANG XZ, LIU MX, et al.Effect and mechanism of Jinzhen Oral Liquid on influenza virus pneumonia in mice[J]. Drugs & Clinic(现代药物与临床), 2023, 38(3): 499-504.
[15] Keogh B, Parker A E.Toll-like receptors as targets for immune disorders[J]. Trends Pharmacol Sci, 2011, 32(7): 435-442.
[16] GALIANA-ARNOUX D, IMLER JL.Toll-like receptors and innate antiviral immunity[J]. Tissue Antigens, 2006, 67(4): 267-276.

疏风解毒胶囊预防给药对流感病毒感染小鼠模型TLR4介导肺组织炎性损伤的影响

Effects of Shufeng Jiedu capsules prophylactic administration on TLR4-mediated inflammatory injury in lung tissue in a mouse model of inffuenza virus infeciton

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	姚伟洁, 闫仕祺, 袁偲偲, 贡磊磊, 冯欣. 养血安胎方对复发性自然流产小鼠胎盘血管生成与自噬的调控作用研究[J]. 中国药物警戒, 2024, 21(4): 371-377.
[2]	黄曙光, 张学农. 多肽BR0336在小鼠2型糖尿病合并非酒精性脂肪性肝炎模型上的初步药效学研究[J]. 中国药物警戒, 2024, 21(4): 415-421.
[3]	孙绮悦, 郭姗姗, 赵荣华, 包蕾, 耿子涵, 李舒冉, 徐英莉, 张敬升, 崔晓兰, 孙静. 变应性鼻炎相关动物模型研究进展[J]. 中国药物警戒, 2024, 21(3): 241-245.
[4]	孙静, 赵荣华, 郭姗姗, 高双荣, 包蕾, 耿子涵, 李舒冉, 孙绮悦, 徐洲, 覃广源, 潘玉杰, 谭秋霞, 龙忠义, 黄成钢, 崔晓兰. BD-77雾化吸入给药对肺炎支原体感染小鼠的治疗作用[J]. 中国药物警戒, 2024, 21(3): 253-256.
[5]	李舒冉, 郭姗姗, 包蕾, 孙静, 赵荣华, 鲍岩岩, 耿子涵, 张宇, 曹姗, 吕耀中, 王振中, 崔晓兰, 王红梅. 佛芍颗粒对功能性腹痛模型小鼠的治疗作用研究[J]. 中国药物警戒, 2024, 21(3): 269-272.
[6]	孙绮悦, 赵荣华, 包蕾, 郭姗姗, 耿子涵, 李舒冉, 徐英莉, 张敬升, 崔晓兰, 孙静. 基于多动物模型药效评价体系研究羚羊感冒口服液儿童用药剂量[J]. 中国药物警戒, 2024, 21(2): 121-126.
[7]	孙绮悦, 赵荣华, 郭姗姗, 包蕾, 耿子涵, 李舒冉, 徐英莉, 张敬升, 崔晓兰, 孙静. 羚羊感冒口服液多重药理作用研究[J]. 中国药物警戒, 2024, 21(2): 127-131.
[8]	赵荣华, 孙静, 包蕾, 耿子涵, 陶夏莉, 张敬升, 庞博, 徐英莉, 曹姗, 李舒冉, 郭姗姗, 王道涵, 崔晓兰. 基于免疫调节探讨葛根汤颗粒治疗小鼠病毒性肺炎的作用机制[J]. 中国药物警戒, 2024, 21(2): 132-136.
[9]	包蕾, 耿子涵, 李舒冉, 冀祖恩, 赵荣华, 孙静, 郭姗姗, 崔晓兰. 瞬时受体电位通道在病毒性肺炎发展过程中的关键作用[J]. 中国药物警戒, 2024, 21(2): 137-140.
[10]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[11]	张宇, 张薇, 高双荣, 陈梦苹, 王雅欣, 徐英莉, 曹姗, 赵荣华, 包蕾, 李舒冉, 孙静, 鲍岩岩, 耿子涵, 郭姗姗, 冀祖恩, 崔晓兰. 基于蛋白质芯片技术筛选与甲型流感病毒NS1蛋白互作的宿主因子及通路分析[J]. 中国药物警戒, 2024, 21(1): 40-44.
[12]	张敬升, 高双荣, 庞博, 刘莉娜, 徐英莉, 曹姗, 陈梦苹, 张宇, 赵荣华, 崔晓兰. 散寒化湿颗粒对人冠状病毒229E和OC43感染致小鼠肺炎的作用机制研究[J]. 中国药物警戒, 2024, 21(1): 51-54.
[13]	张亮亮, 胡昌坤, 吴泽坤, 周维, 廖泽彬, 高月. 富马酸二甲酯对肠道辐射损伤防护作用及机制研究[J]. 中国药物警戒, 2024, 21(1): 83-88.
[14]	张立, 汪余嘉, 张玲玲, 陈家鑫, 林敏华, 林小惠, 聂雪坤. 真实世界免疫检查点抑制剂相关不良反应监测数据分析[J]. 中国药物警戒, 2023, 20(9): 1035-1038.
[15]	殷玉玲, 胡楚涓, 张晓朦, 王雨, 张冰, 林志健. 菊苣提取物抗阿霉素心脏毒性作用挖掘及验证[J]. 中国药物警戒, 2023, 20(8): 858-865.